The JAK3-selective inhibitor PF-956980 reverses the resistance to cytotoxic agents induced by interleukin-4 treatment of chronic lymphocytic leukemia cells: potential for reversal of cytoprotection by the microenvironment - PubMed (original) (raw)
. 2010 Nov 25;116(22):4569-77.
doi: 10.1182/blood-2009-09-245811. Epub 2010 Aug 17.
Affiliations
- PMID: 20716767
- DOI: 10.1182/blood-2009-09-245811
Free article
The JAK3-selective inhibitor PF-956980 reverses the resistance to cytotoxic agents induced by interleukin-4 treatment of chronic lymphocytic leukemia cells: potential for reversal of cytoprotection by the microenvironment
Andrew J Steele et al. Blood. 2010.
Free article
Abstract
Extensive evidence suggests that the malignant cells of chronic lymphocytic leukemia (CLL) patients are in close contact with activated T lymphocytes, which secrete a range of cytoprotective cytokines including interleukin-4 (IL-4). IL-4 induced the rapid phosphorylation and activation of the signal transducer and activator of transcription 6 transcription factor in CLL cells in vitro. Longer incubation with IL-4 resulted in up-regulation of the antiapoptotic proteins, Mcl-1 and Bcl-X(L). All of these events were blocked by the JAK3-selective inhibitor, PF-956980. A dye reduction cytotoxicity assay showed that IL-4 induced resistance to the cytotoxic drugs fludarabine and chlorambucil and to the novel p53-elevating agent nutlin 3. IL-4-induced drug resistance was reversed by PF-956980. These conclusions were confirmed by independent assays for apoptosis induction (annexin V binding, cleavage of poly[ADP-ribose] polymerase, and morphologic analysis). Coculture with bone marrow stromal cells in the presence of supernatants derived from activated T-lymphocyte cultures also protected CLL cells from apoptosis induction by chlorambucil. Protection by these combined signals was reversed by PF-956980. The data here provide a preclinical rationale for the possible therapeutic use of PF-956980 in conjunction with conventional cytotoxic drugs to achieve more extensive killing of CLL cells by overcoming antiapoptotic signaling by the microenvironment.
Similar articles
- The STAT3 inhibitor WP1066 reverses the resistance of chronic lymphocytic leukemia cells to histone deacetylase inhibitors induced by interleukin-6.
Lu K, Fang XS, Feng LL, Jiang YJ, Zhou XX, Liu X, Li PP, Chen N, Ding M, Wang N, Zhang J, Wang X. Lu K, et al. Cancer Lett. 2015 Apr 10;359(2):250-8. doi: 10.1016/j.canlet.2015.01.021. Epub 2015 Jan 27. Cancer Lett. 2015. PMID: 25636517 - 2-Phenylacetylenesulfonamide (PAS) induces p53-independent apoptotic killing of B-chronic lymphocytic leukemia (CLL) cells.
Steele AJ, Prentice AG, Hoffbrand AV, Yogashangary BC, Hart SM, Lowdell MW, Samuel ER, North JM, Nacheva EP, Chanalaris A, Kottaridis P, Cwynarski K, Wickremasinghe RG. Steele AJ, et al. Blood. 2009 Aug 6;114(6):1217-25. doi: 10.1182/blood-2008-11-190587. Epub 2009 Jun 10. Blood. 2009. PMID: 19515722 - Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53.
Byrd JC, Shinn C, Waselenko JK, Fuchs EJ, Lehman TA, Nguyen PL, Flinn IW, Diehl LF, Sausville E, Grever MR. Byrd JC, et al. Blood. 1998 Nov 15;92(10):3804-16. Blood. 1998. PMID: 9808574 - Dasatinib inhibits B cell receptor signalling in chronic lymphocytic leukaemia but novel combination approaches are required to overcome additional pro-survival microenvironmental signals.
McCaig AM, Cosimo E, Leach MT, Michie AM. McCaig AM, et al. Br J Haematol. 2011 Apr;153(2):199-211. doi: 10.1111/j.1365-2141.2010.08507.x. Epub 2011 Feb 24. Br J Haematol. 2011. PMID: 21352196 Clinical Trial. - Inhibition of NF-κB-mediated signaling by the cyclin-dependent kinase inhibitor CR8 overcomes prosurvival stimuli to induce apoptosis in chronic lymphocytic leukemia cells.
Cosimo E, McCaig AM, Carter-Brzezinski LJ, Wheadon H, Leach MT, Le Ster K, Berthou C, Durieu E, Oumata N, Galons H, Meijer L, Michie AM. Cosimo E, et al. Clin Cancer Res. 2013 May 1;19(9):2393-405. doi: 10.1158/1078-0432.CCR-12-2170. Epub 2013 Mar 26. Clin Cancer Res. 2013. PMID: 23532892
Cited by
- Ibrutinib in Chronic Lymphocytic Leukemia: Clinical Applications, Drug Resistance, and Prospects.
Zhou H, Hu P, Yan X, Zhang Y, Shi W. Zhou H, et al. Onco Targets Ther. 2020 May 29;13:4877-4892. doi: 10.2147/OTT.S249586. eCollection 2020. Onco Targets Ther. 2020. PMID: 32581549 Free PMC article. Review. - A hybrid energy-based and AI-based screening approach for the discovery of novel inhibitors of JAK3.
Wei J, Pan Y, Shen Z, Shen L, Xu L, Yu W, Huang W. Wei J, et al. Front Med (Lausanne). 2023 Oct 10;10:1182227. doi: 10.3389/fmed.2023.1182227. eCollection 2023. Front Med (Lausanne). 2023. PMID: 37886358 Free PMC article. - The SF3B1 inhibitor spliceostatin A (SSA) elicits apoptosis in chronic lymphocytic leukaemia cells through downregulation of Mcl-1.
Larrayoz M, Blakemore SJ, Dobson RC, Blunt MD, Rose-Zerilli MJ, Walewska R, Duncombe A, Oscier D, Koide K, Forconi F, Packham G, Yoshida M, Cragg MS, Strefford JC, Steele AJ. Larrayoz M, et al. Leukemia. 2016 Feb;30(2):351-60. doi: 10.1038/leu.2015.286. Epub 2015 Oct 21. Leukemia. 2016. PMID: 26488112 - STAT6 deficiency ameliorates Graves' disease severity by suppressing thyroid epithelial cell hyperplasia.
Jiang X, Zha B, Liu X, Liu R, Liu J, Huang E, Qian T, Liu J, Wang Z, Zhang D, Wang L, Chu Y. Jiang X, et al. Cell Death Dis. 2016 Dec 1;7(12):e2506. doi: 10.1038/cddis.2016.398. Cell Death Dis. 2016. PMID: 27906181 Free PMC article. - GIFT4 fusokine converts leukemic B cells into immune helper cells.
Deng J, Pennati A, Cohen JB, Wu Y, Ng S, Wu JH, Flowers CR, Galipeau J. Deng J, et al. J Transl Med. 2016 Apr 27;14(1):106. doi: 10.1186/s12967-016-0865-1. J Transl Med. 2016. PMID: 27118475 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous